Urine test could help to guide treatment of bladder cancer
the ONA take:
According to new research published in the British Journal of Cancer, researchers at the University of Birmingham in Birmingham, United Kingdom, have identified two prognostic urinary biomarkers, epidermal growth factor receptor (EGFR) and epithelial cell adhesion molecule (epCAM), that could help to guide clinicians in the treatment of patients with bladder cancer.
In the study, researchers found that both urinary EGFR and EpCAM were found to be independent predictors of bladder cancer-specific survival when validated in over 400 clinical samples. In addition, both have prognostic value over any standard clinical and pathological observations. Results showed that higher levels of the biomarkers were associated with more aggressive cases of cancer and poor survival outcomes.
The researchers note that a non-invasive prognostic test could make treatment of the disease much more efficient, allow for a refinement of surveillance strategies according to risk, and reduce visits to a clinician. The authors point out that these biomarkers cannot be utilized to diagnose bladder cancer.
The American Cancer Society estimates that there will be about 74,000 new cases of bladder cancer diagnosed in the United States in 2015 and about 16,000 deaths from the disease.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|